Eton Pharmaceuticals Inc. (ETON)
Eton Pharmaceuticals Statistics
Share Statistics
Eton Pharmaceuticals has 26.82M shares outstanding. The number of shares has increased by 4.39% in one year.
Shares Outstanding | 26.82M |
Shares Change (YoY) | 4.39% |
Shares Change (QoQ) | 0.69% |
Owned by Institutions (%) | 50.72% |
Shares Floating | 25.33M |
Failed to Deliver (FTD) Shares | 10 |
FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 191.94K, so 0.72% of the outstanding shares have been sold short.
Short Interest | 191.94K |
Short % of Shares Out | 0.72% |
Short % of Float | 0.76% |
Short Ratio (days to cover) | 0.93 |
Valuation Ratios
The PE ratio is -90.22 and the forward PE ratio is 33.08. Eton Pharmaceuticals's PEG ratio is -0.29.
PE Ratio | -90.22 |
Forward PE | 33.08 |
PS Ratio | 8.84 |
Forward PS | 1.5 |
PB Ratio | 14.12 |
P/FCF Ratio | 365.77 |
PEG Ratio | -0.29 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Eton Pharmaceuticals.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.06, with a Debt / Equity ratio of 0.
Current Ratio | 2.06 |
Quick Ratio | 1.29 |
Debt / Equity | 0 |
Debt / EBITDA | -0.04 |
Debt / FCF | 0.11 |
Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $1.26M |
Profits Per Employee | $-123.32K |
Employee Count | 31 |
Asset Turnover | 0.51 |
Inventory Turnover | 1.02 |
Taxes
Income Tax | 15K |
Effective Tax Rate | -0.39% |
Stock Price Statistics
The stock price has increased by 247.28% in the last 52 weeks. The beta is 1.37, so Eton Pharmaceuticals's price volatility has been higher than the market average.
Beta | 1.37 |
52-Week Price Change | 247.28% |
50-Day Moving Average | 15.44 |
200-Day Moving Average | 9.38 |
Relative Strength Index (RSI) | 36.21 |
Average Volume (20 Days) | 292.75K |
Income Statement
In the last 12 months, Eton Pharmaceuticals had revenue of 39.01M and earned -3.82M in profits. Earnings per share was -0.15.
Revenue | 39.01M |
Gross Profit | 23.41M |
Operating Income | -2.6M |
Net Income | -3.82M |
EBITDA | -2.6M |
EBIT | -2.6M |
Earnings Per Share (EPS) | -0.15 |
Balance Sheet
The company has 14.94M in cash and 107K in debt, giving a net cash position of 14.83M.
Cash & Cash Equivalents | 14.94M |
Total Debt | 107K |
Net Cash | 14.83M |
Retained Earnings | -107.89M |
Total Assets | 76.12M |
Working Capital | 21.07M |
Cash Flow
In the last 12 months, operating cash flow was 969K and capital expenditures -26K, giving a free cash flow of 943K.
Operating Cash Flow | 969K |
Capital Expenditures | -26K |
Free Cash Flow | 943K |
FCF Per Share | 0.04 |
Margins
Gross margin is 60.01%, with operating and profit margins of -6.66% and -9.8%.
Gross Margin | 60.01% |
Operating Margin | -6.66% |
Pretax Margin | -9.76% |
Profit Margin | -9.8% |
EBITDA Margin | -6.66% |
EBIT Margin | -6.66% |
FCF Margin | 2.42% |
Dividends & Yields
ETON does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for ETON is $26, which is 103.4% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $26 |
Price Target Difference | 103.4% |
Analyst Consensus | Strong Buy |
Analyst Count | 3 |
Scores
Altman Z-Score | 2.79 |
Piotroski F-Score | 4 |